TrimRx's Blog

Introduction Compounded tirzepatide in 2026 is made primarily by 503A compounding pharmacies operating under section 503A of the Federal Food Drug and Cosmetic Act….

Compounded semaglutide is made by licensed 503A compounding pharmacies and, in limited cases, 503B outsourcing facilities registered with the FDA.

PT-141, also known by its generic name bremelanotide and the brand name Vyleesi, is a melanocortin receptor agonist used for low sexual desire.

Running out of semaglutide or tirzepatide between refills is more common than the FDA shortage status suggests.

Six-month tirzepatide weight loss averages roughly 12 to 18 percent of starting body weight at the higher maintenance doses (10 to 15 mg weekly).

Introduction Most people lose 5 to 10% of their starting body weight in the first 3 months on semaglutide, which translates to roughly 10…

Introduction First-month weight loss on GLP-1 medications typically ranges from 2 to 5 percent of starting body weight, which translates to roughly 4 to…

Wegovy does not produce chemical withdrawal. There is no shaking, no rebound anxiety from receptor adaptation, no seizure risk.

Wegovy is semaglutide 2.4 mg dosed once weekly for chronic weight management. The phase 3 STEP 1 trial (Wilding et al.